Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.

Rubie H, De Bernardi B, Gerrard M, Canete A, Ladenstein R, Couturier J, Ambros P, Munzer C, Pearson AD, Garaventa A, Brock P, Castel V, Valteau-Couanet D, Holmes K, Di Cataldo A, Brichard B, Mosseri V, Marquez C, Plantaz D, Boni L, Michon J.

J Clin Oncol. 2011 Feb 1;29(4):449-55. doi: 10.1200/JCO.2010.29.5196. Epub 2010 Dec 20.

PMID:
21172879
2.

Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy.

Rubie H, Coze C, Plantaz D, Munzer C, Defachelles AS, Bergeron C, Thomas C, Chastagner P, Valteau-Couanet D, Michon J, Mosseri V, Hartmann O; Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique..

Br J Cancer. 2003 Nov 3;89(9):1605-9.

3.

Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study.

Kohler JA, Rubie H, Castel V, Beiske K, Holmes K, Gambini C, Casale F, Munzer C, Erminio G, Parodi S, Navarro S, Marquez C, Peuchmaur M, Cullinane C, Brock P, Valteau-Couanet D, Garaventa A, Haupt R.

Eur J Cancer. 2013 Nov;49(17):3671-9. doi: 10.1016/j.ejca.2013.07.002. Epub 2013 Jul 29.

PMID:
23907002
4.

N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.

Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, Baranzelli MC, Plantaz D, Avet-Loiseau H, Bénard J, Delattre O, Favrot M, Peyroulet MC, Thyss A, Perel Y, Bergeron C, Courbon-Collet B, Vannier JP, Lemerle J, Sommelet D.

J Clin Oncol. 1997 Mar;15(3):1171-82.

PMID:
9060561
5.

Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique.

Rubie H, Plantaz D, Coze C, Michon J, Frappaz D, Baranzelli MC, Chastagner P, Peyroulet MC, Hartmann O; Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique..

Med Pediatr Oncol. 2001 Jan;36(1):247-50.

PMID:
11464897
6.

Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.

Bomken S, Davies B, Chong L, Cole M, Wood KM, McDermott M, Tweddle DA.

Pediatr Hematol Oncol. 2011 Mar;28(2):106-14. doi: 10.3109/08880018.2010.526684. Epub 2011 Jan 8.

PMID:
21214410
7.

Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.

Bagatell R, Rumcheva P, London WB, Cohn SL, Look AT, Brodeur GM, Frantz C, Joshi V, Thorner P, Rao PV, Castleberry R, Bowman LC.

J Clin Oncol. 2005 Dec 1;23(34):8819-27.

PMID:
16314642
8.

Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.

Kushner BH, Modak S, Kramer K, LaQuaglia MP, Yataghene K, Basu EM, Roberts SS, Cheung NK.

Cancer. 2014 Jul 1;120(13):2050-9. doi: 10.1002/cncr.28687. Epub 2014 Apr 1.

9.

Management and outcome of stage 3 neuroblastoma.

Modak S, Kushner BH, LaQuaglia MP, Kramer K, Cheung NK.

Eur J Cancer. 2009 Jan;45(1):90-8. doi: 10.1016/j.ejca.2008.09.016. Epub 2008 Nov 6.

10.

Successful treatment of infants with localized neuroblastoma based on their MYCN status.

Iehara T, Hamazaki M, Tajiri T, Kawano Y, Kaneko M, Ikeda H, Hosoi H, Sugimoto T, Sawada T; Japanese Infantile Neuroblastoma Cooperative Study Group..

Int J Clin Oncol. 2013 Jun;18(3):389-95. doi: 10.1007/s10147-012-0391-y. Epub 2012 Mar 2.

PMID:
22383024
11.

Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.

Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K, Iwafuchi M, Sawada T, Suita S.

J Pediatr Hematol Oncol. 2002 Nov;24(8):613-21.

PMID:
12439032
12.

Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study.

Bowman LC, Castleberry RP, Cantor A, Joshi V, Cohn SL, Smith EI, Yu A, Brodeur GM, Hayes FA, Look AT.

J Natl Cancer Inst. 1997 Mar 5;89(5):373-80.

PMID:
9060959
13.

Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.

Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, Monclair T, Ambros PF, Cohn SL; International Neuroblastoma Risk Group..

J Clin Oncol. 2009 Jan 20;27(3):365-70. doi: 10.1200/JCO.2008.17.9184. Epub 2008 Dec 1.

14.

Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors.

Garaventa A, Boni L, Lo Piccolo MS, Tonini GP, Gambini C, Mancini A, Tonegatti L, Carli M, di Montezemolo LC, Di Cataldo A, Casale F, Mazzocco K, Cecchetto G, Rizzo A, Bernardi B; Italian Cooperative Group for Neuroblastoma..

Ann Oncol. 2002 Jun;13(6):956-64.

PMID:
12123342
15.

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).

Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, Munzer C, Bénard J, Auger N, Combaret V, Janoueix-Lerosey I, Pearson A, Tweddle DA, Bown N, Gerrard M, Wheeler K, Noguera R, Villamon E, Cañete A, Castel V, Marques B, de Lacerda A, Tonini GP, Mazzocco K, Defferrari R, de Bernardi B, di Cataldo A, van Roy N, Brichard B, Ladenstein R, Ambros I, Ambros P, Beiske K, Delattre O, Couturier J.

Br J Cancer. 2011 Dec 6;105(12):1940-8. doi: 10.1038/bjc.2011.472. Epub 2011 Nov 10.

16.

Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.

Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL.

J Clin Oncol. 2008 Feb 20;26(6):913-8. doi: 10.1200/JCO.2007.13.9493.

PMID:
18281664
17.

Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?

Di Cataldo A, Agodi A, Balaguer J, Garaventa A, Barchitta M, Segura V, Bianchi M, Castel V, Castellano A, Cesaro S, Couselo JM, Cruz O, D'Angelo P, De Bernardi B, Donat J, de Andoin NG, Hernandez MI, La Spina M, Lillo M, Lopez-Almaraz R, Luksch R, Mastrangelo S, Mateos E, Molina J, Moscheo C, Mura R, Porta F, Russo G, Tondo A, Torrent M, Vetrella S, Villegas JA, Viscardi E, Zanazzo GA, Cañete A.

Clin Transl Oncol. 2017 Jan;19(1):76-83. doi: 10.1007/s12094-016-1505-1. Epub 2016 Apr 4.

PMID:
27041689
18.

Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.

Canete A, Gerrard M, Rubie H, Castel V, Di Cataldo A, Munzer C, Ladenstein R, Brichard B, Bermúdez JD, Couturier J, de Bernardi B, Pearson AJ, Michon J.

J Clin Oncol. 2009 Mar 1;27(7):1014-9. doi: 10.1200/JCO.2007.14.5839. Epub 2009 Jan 26.

PMID:
19171715
19.

Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.

van Wezel EM, Decarolis B, Stutterheim J, Zappeij-Kannegieter L, Berthold F, Schumacher-Kuckelkorn R, Simon T, Fiocco M, van Noesel MM, Caron HN, van der Schoot CE, Hero B, Tytgat GA.

Eur J Cancer. 2016 Feb;54:149-58. doi: 10.1016/j.ejca.2015.11.007. Epub 2016 Jan 12.

PMID:
26796600
20.

High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.

Laprie A, Michon J, Hartmann O, Munzer C, Leclair MD, Coze C, Valteau-Couanet D, Plantaz D, Carrie C, Habrand JL, Bergeron C, Chastagner P, Défachelles AS, Delattre O, Combaret V, Bénard J, Pérel Y, Gandemer V, Rubie H; Neuroblastoma Study Group of the French Society of Pediatric Oncology..

Cancer. 2004 Sep 1;101(5):1081-9.

Supplemental Content

Support Center